<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0407245479
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1994
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROSTIN E2 0.5ML I.V.AMP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DINOPROSTONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        112.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G02AD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Prostin E2 concentrate for solution for infusion contains the prostaglandin dinoprostone and is used to &ldquo;induce&rdquo; labour. This means that the medicine will help your uterus (womb) to start contracting and you will go into labour which will end the pregnancy. This is also called termination of pregnancy or an abortion. Dinoprostone is similar to the natural &lsquo;E2&rsquo; type of prostaglandins which are made in your body when labour starts. It is an infusion which will be given into your blood through a vein (intravenous). It will only be given to you in a hospital or clinic which has a specialised obstetric unit.</p><p>&nbsp;</p><p>You could need this treatment for different reasons:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your baby has died in your womb</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if it is required to end your pregnancy for health reasons</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an abnormal growth of the placenta called a &lsquo;hydatidiform mole&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Most women can be treated with Prostin E2. Some women may need extra checks during treatment and for some women a different treatment may be better. Your doctor or nurse will ask you questions before giving you Prostin E2 to make sure it is safe for you. If you do not understand any of the questions, ask your doctor or nurse to explain.</p><p>&nbsp;</p><p>If you are having a pregnancy termination (abortion), it is very important for it to be complete. This is because prostaglandins given at this stage in pregnancy may cause abnormalities in the foetus. If your doctor thinks that the abortion has not worked completely, you will need another treatment, probably an operation.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><strong>Do not take Prostin E2:</strong></p><p>&nbsp;</p><ul><li>If you are allergic to dinoprostone or any other prostaglandin or any of the other ingredients of this medicine (listed in section 6). Signs of an allergic reaction include wheezing, breathlessness, swelling of the hands, face, itchy rash or redness of the skin.</li></ul><p>&nbsp;</p><p>Your doctor or nurse will not use Prostin E2 to start or strengthen your labour in certain circumstances if:</p><ul><li>you have had a Caesarean section or any major surgery to your womb in the past.</li><li>you have been told that you will have an obstructed labour.</li><li>you have an infection of your womb, ovaries or tubes (pelvic inflammatory disease) unless you are receiving treatment for these, or if you have ever had such an infection in the past.</li><li>you have current heart, lung, kidney or liver disease.</li></ul><p>&nbsp;</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or nurse before they use this medicine if you have or have had in the past any of the following conditions as they may want to monitor you more closely:</p><ul><li>heart, lung, kidney or liver disease</li><li>glaucoma (raised pressure in the eye)</li><li>epilepsy</li><li>suffered from asthma</li><li>hypertension (high blood pressure) at any time, including during this or any previous pregnancy</li><li>been told you had abnormally strong contractions of your womb during a previous labour</li><li>scarring of your womb from a previous operation</li><li>are you 35 years or older?</li><li>is your pregnancy over 40 weeks?</li><li>do you have any complications related to this pregnancy?</li><li>an increased risk of developing a generalised bleeding disorder, a condition known as post-partum disseminated coagulation.</li><li>if you are having more than one baby</li><li>if your water has broken.</li></ul><p><strong>&nbsp;</strong></p><p>Your doctor or nurse will ask you questions before giving you Prostin E2 for infusion to make sure it is safe for you.</p><p>&nbsp;</p><p>If you do not understand any of the questions, ask your doctor or nurse to explain.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Prostin E2</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>&nbsp;</strong></p><p>Prostin E2 can make you more sensitive to another medicine called oxytocin which is used to strengthen contractions. Medical staff will normally try not to use this medicine at the same time as Prostin E2. If used with this medicine in sequence, your doctor or nurse will watch over the womb contractions very carefully.</p><p>&nbsp;</p><p><strong>Prostin E2 with food, drink and alcohol</strong></p><p><strong>&nbsp;</strong></p><p>Not applicable</p><p>&nbsp;</p><p><strong>Pregnancy and , Lactation and fertility</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;Prostin E2 concentrate for solution for infusion will only be given to you in the late stages of pregnancy to induce labour. Prostin E2 Sterile Solution is only used during pregnancy for therapeutic termination of pregnancy, missed abortion and hydatidiform mole.</p><p>&nbsp;</p><p>Although prostaglandins are present in breast-milk, you are not expected to be breast-feeding as this medicine is used to terminate the pregnancy.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Prostin E2 concentrate for solution for infusion contains alcohol (ethanol)</strong></p><p><strong>&nbsp;</strong></p><p>PROSTIN E2 0.75 mg contains 600 mg of alcohol (ethanol) in each 0.75 ml ampoule which is equivalent to 800 mg/ml (80% w/v) (see section 2). The amount in each 0.75 ml ampoule of this medicine is equivalent to less than 15 ml beer or 6 ml wine.</p><p>&nbsp;</p><p>PROSTIN E2 5 mg contains 400 mg of alcohol (ethanol) in each 0.5 ml ampoule which is equivalent to 800 mg/ml (80% w/v) (see section 2). The amount in each 0.5 ml ampoule of this medicine is equivalent to less than 10 ml beer or 4 ml wine.</p><p><strong>&nbsp;</strong></p><p>The small amount of alcohol in this medicine will not have any noticeable effects.</p><p><strong>&nbsp;</strong></p><p>Depending on the daily dose given to you this medicinal product will deliver different amounts of ethanol.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p>In view of the indication for Prostin E2 , this section is not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Prostin E2 will be given to you by a trained professional in a hospital or clinic where facilities for monitoring you and your baby are available. Medical staff will be available at all times.</p><p>&nbsp;</p><p>DIRECTIONS FOR THE PREPARATION OF DILUTE SOLUTIONS</p><p>&nbsp;</p><p>A.&nbsp;&nbsp;&nbsp; From the 1 mg/ml concentrate for solution for infusion:<br />For intravenous use for the induction of labor (1.5&nbsp;&micro;g/ml dilute infusion).<br />For use by I.V. drip (a drip set delivering 60 drops per ml must be used) or constant rate infusion pump: withdraw 0.75 ml of the 1&nbsp;mg/ml preparation using an aseptic technique, and add to 500&nbsp;ml sterile normal saline or 5% sterile aqueous dextrose solution.&nbsp; Shake to ensure uniformity. &nbsp;Diluted solution must be used within 24 hours of preparation.</p><p>B.&nbsp;&nbsp;&nbsp;&nbsp; From the 10 mg/ml concentrate for solution for infusion:<br />For intravenous use for fetus retention and hydatidiform mole (5.0&nbsp;&micro;g/ml dilute infusion).<br />For use by I.V. drip (a drip set delivering 60 drops per ml must be used) or a constant rate infusion pump: withdraw 0.5&nbsp;ml of the 10&nbsp;mg/ml preparation using an aseptic technique, and add to 1000&nbsp;ml sterile normal saline or 5% sterile aqueous dextrose solution (or 0.25 ml to 500 ml).&nbsp; Shake to ensure uniformity.&nbsp; Diluted solution must be used within 24 hours of preparation.</p><p>&nbsp;</p><p>POSOLOGY</p><p>&nbsp;</p><p>In all cases the dose should be adapted to the patient.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp; For induction of labor by the intravenous route (1.5 &micro;g/ml diluted solution for infusion):<br />The initial rate of infusion should be 0.25 &micro;g/min., which should be maintained for at least the first 30 minutes.&nbsp; If a satisfactory uterine contractility response is produced, this rate should be maintained.&nbsp; If not, the rate may be increased to 0.5&nbsp;&micro;g/min..&nbsp; In some circumstances, after a fair trial (one or two hours), the rate may be increased to 1.0 &micro;g/min. or, rarely, 2.0 &micro;g/min. to produce a satisfactory contractility, but increases should be made in the light of undesirable effects and uterine response.&nbsp; If uterine hypertonus or fetal distress occurs, the infusion should be stopped until the condition of the patient and the fetus returns to normal.&nbsp; The infusion may then be recommended at 50% of the last dose level and subsequently increased with caution.<br />Cases of foetal death in utero may require higher doses than those given above.&nbsp; An initial rate of 0.5 &micro;g/min. may be used with stepwise increased at intervals of not less than one hour as described above.&nbsp; Undesirable effects permitting, the final rate of infusion may be increased to 4.0&nbsp;&micro;g/min. if uterine contractility response is inadequate at the lower dosage rates. Continuous administration of the drug for more than two days is not recommended.</p><p>2.&nbsp;&nbsp;&nbsp; For the management of fetus retention and hydatidiform mole by the intravenous route (5.0 &micro;g/ml diluted solution for infusion):<br />The initial rate of infusion will be 2.5 &micro;g/min., and this rate should be maintained for at least the first 30 minutes.&nbsp; If satisfactory uterine contractility response is produced, this rate should be maintained; if not, the rate should be increased to 5 &micro;g/min.&nbsp; If satisfactory uterine activity is not produced after at least 4 hours at this rate of infusion, the rate may be increased up to 10 &micro;g/min., undesirable effects permitting, and maintained until evacuation of the uterine content occurs or the treatment is considered a failure.&nbsp; If significant undesirable effects occur, the rate of infusion should be decreased by 50% or discontinued.<br />Dependent on the type of infusion pump, a different concentration of solution (e.g. 15 &micro;g/ml) may be required, but the infused dose rate (&micro;g/min) should remain as above.</p><p>&nbsp;</p><p>The doctor or nurse will keep a very close eye on you during your treatment to make sure that the contractions do not become too strong, as this could cause your uterus to tear. They should be able to act quickly if you have side effects or if your womb reacts too strongly to the dose you are given. You might just need a lower dose, or you might need some other obstetric procedure.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Prostin E2 in paediatric patients has not been established.&nbsp; There is no relevant use of Prostin E2 in paediatric patients other than adolescents.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>If you are given more Prostin E2 than you should</strong></p><p><strong>&nbsp;</strong></p><p>Tell your doctor or nurse if you think you have been given too much Prostin E2. Symptoms of this would be excessive contractions of your womb (very strong, frequent and painful contractions) or severe side effects, such as feeling and being sick. If you have such symptoms, the rate at which Prostin E2 is being given should be reduced, or the treatment should be stopped. If you have a massive overdose, so that the muscles of your womb become very tense and over-active or ruptures, you might need another obstetric procedure.</p><p>&nbsp;</p><p>Your doctor or nurse will do internal checks to make sure that your cervix is opening enough. They will also check your contractions to make sure that they are not too strong.</p><p>&nbsp;</p><p>As prostaglandins make the body go into labour in the same way as it would happen naturally, anything that can happen in a natural labour can also happen if you have been given Prostin E2 Sterile Solution.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you have asthma, Prostin E2 could cause you to have an asthmatic attack by causing a narrowing of your airways (bronchospasm). <strong>You must tell your doctor or nurse if you suffer from asthma or if you start having difficulty in breathing.</strong></p><p>&nbsp;</p><p><strong>Other reported side effects include</strong>:</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (being sick)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormally strong, frequent or long contractions of the womb</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of discomfort or reddeness at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; APGAR score low</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal foetal heart rate</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people</strong></p><ul><li>Vaso-vagal symptoms (flushing, shivering, headache, dizziness)</li><li>High blood pressure in the mother</li><li>Foetal distress</li></ul><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon (may affect up to 1 in 100 people):</u></strong><strong> </strong></p><ul><li>Seizure</li><li>Low blood pressure</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchospasm</p><ul><li>Rash</li><li>Detached placenta</li><li>Running a high temperature</li></ul><p>&nbsp;</p><p><strong><u>Rare (may affect up to 1 in 1,000 people):</u></strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Bleeding</p><p>&nbsp;</p><p><strong><u>Not known: frequency cannot be estimated from the available data</u></strong></p><ul><li>Sudden blockage of a blood vessel with amniotic fluid (the fluid which surrounds the baby) or by a blood clot in the lungs. This could cause chest pain and shortness of breath.</li><li>Very quick opening of the cervix</li><li>Backache</li><li>Foetal death, stillbirth and death of the newborn baby (neonatal death); especially following serious events such as tearing of the womb.</li><li>Tearing or bursting of the wall of your womb (uterine rupture)</li><li>Heart attack</li><li>Allergic/anaphylactic reactions, including anaphylactic shock (serious allergic reactions which can include skin rash, itching, wheezing, shortness of breath, swollen face, lips, hands, fingers, neck and throat, sudden drop in blood pressure, abdominal pain and collapse).</li></ul><p>&nbsp;</p><p><strong>If you get any of these symptoms please tell your doctor or nurse straight away.</strong></p><p>&nbsp;</p><p>Talk to your doctor or nurse about this if you want to know more, as they will be able to give you the information that you need.</p><p>&nbsp;</p><p>In some women the number of white blood cells rises during treatment. This will not cause you any symptoms, but your doctor or nurse may mention this if you have a blood sample taken.</p><p>&nbsp;</p><p>You might have reddening and irritation in the area around the needle for two to five hours after the needle has been removed.</p><p>&nbsp;</p><p>A higher risk of a generalised bleeding disorder following delivery (post-partum disseminated intravascular coagulation-DIC) has been described in women who:</p><ul><li>are aged 35 and above.</li><li>whose pregnancies are more than 40 weeks.</li><li>who have pregnancy-related complications.</li></ul><p>&nbsp;</p><p><strong>Reporting of side effects:</strong><br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Saudi Arabia: </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;Other GCC States:</strong></p><p><em>&nbsp;</em></p><p> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store in refrigerator (2&deg;‑8&deg;C).</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Keep Prostin E2 out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use Prostin E2 after the expiry date which is stated on the label, carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater . Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance:</p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROSTIN E2 0.75 mg concentrate for solution for infusion contains 1 mg dinoprostone in 1 ml solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROSTIN E2 5 mg concentrate for solution for infusion contains 10 mg dinoprostone in 1 ml solution.</p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient(s) :</p><p>&nbsp;</p><p>- PROSTIN E2&nbsp;&nbsp; 0.75 mg concentrate for solution for infusion: ethanol anhydrous.</p><p>- PROSTIN E2&nbsp;&nbsp; 5 mg concentrate for solution for infusion: ethanol anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                –	PROSTIN E2   0.75 mg concentrate for solution for infusion: 1 ampoule with 0.75 ml solution 1 mg/ml.
–	PROSTIN E2   5 mg concentrate for solution for infusion: 1 ampoule with 0.5 ml solution 10 mg/ml.

Not all presentations may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer S.A., 17 Boulevard de la Plaine, 1050 Brussels, Belgium.</p><p>&nbsp;</p><p><strong>Manufactured, Packed and Released by:</strong></p><p>Pfizer Manufacturing Belgium N.V, Rijsweg 12, Puurs, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي ركازة بروستين إي ٢ لتحضير محلول للتسريب على البروستاجلاندين دينوبروستون ويستخدم ذلك من أجل &quot;تحفيز&quot; المخاض. ويعني هذا أن الدواء سوف يساعد رحمكِ على البدء في الانقباض وستدخلين في مرحلة المخاض وسيكون ذلك نهاية الحمل. يسمى ذلك أيضًا بإنهاء الحمل أو الإجهاض. يشبه دينوبروستون النوع &quot;إي ٢&quot; من البروستاجلاندينات الطبيعية التي يتم تصنيعها في جسمكِ عند بدء المخاض. وهو عبارة عن محلول تسريب يُعطى لكِ في الدم عبر وريد (عن طريق الوريد). سوف يتم إعطاؤه لكِ فقط في إحدى المستشفيات أو العيادات ذات وحدات الولادة المتخصصة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;قد تحتاجين إلى هذا العلاج لأسباب مختلفة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا مات طفلكِ في رحمكِ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان من الضروري إنهاء حملكِ لأسباب صحية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديكِ نمو غير طبيعي في المشيمة يسمى &quot;الحمل العنقودي&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;يمكن علاج أغلب السيدات باستخدام بروستين إي ٢. قد تحتاج بعض السيدات إلى الخضوع لمزيد من الفحوصات أثناء العلاج وقد يكون من الأفضل لبعض السيدات استخدام علاج مختلف. سوف يطرح عليكِ طبيبكِ أو الممرضة أسئلة قبل إعطائكِ بروستين إي ٢ للتأكد من أنه آمن بالنسبة لكِ. إذا لم تفهمي أيًا من الأسئلة، فاطلبي من طبيبكِ أو الممرضة التوضيح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ تخضعين لإنهاء الحمل (الإجهاض)، فمن المهم جدًا أن يكتمل. وذلك لأن البروستاجلاندينات التي تُعطى في هذه المرحلة من الحمل قد تسبب تشوهات في الجنين. إذا اعتقد طبيبكِ أن الإجهاض لم يتم بشكل كامل، فستحتاجين إلى علاج آخر وعلى الأغلب ستحتاجين إلى عملية جراحية.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>موانع استعمال بروستين إي ٢:</strong></p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">إذا كنتِ مصابة بالحساسية تجاه دينوبروستون أو أي بروستاجلاندين آخر أو أي من المكونات الأخرى لهذا الدواء (المدرجة في &nbsp;القسم ٦). تتضمن علامات تفاعل الحساسية الأزيز، أو ضيق التنفس، أو تورم اليدين أو الوجه، أو الطفح الجلدي المثير للحكة، أو احمرار الجلد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;لن يستخدم طبيبكِ أو الممرضة بروستين إي ٢ لبدء أو تقوية المخاض لديكِ في بعض الحالات إذا:</p><ul><li dir="RTL">كنتِ قد خضعتِ لولادة قيصرية أو أي جراحة كبرى في الرحم في الماضي.</li><li dir="RTL">تم إخباركِ أنك ستواجهين عسر الولادة.</li><li dir="RTL">&nbsp;كنتِ مصابة بعدوى في الرحم أو المبيضين أو قناتي فالوب (مرض التهابي بالحوض) إلا إذا كنتِ تتلقين علاجًا لهذه الحالات، أو إذا كان قد سبق لكِ أن أصبتِ بهذه العدوى في السابق.</li><li dir="RTL">إذا كنتِ مصابة في الوقت الحاضر بمرض في القلب، أو الرئة، أو الكلى، أو الكبد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال بروستين إي ٢</strong></p><p dir="RTL">&nbsp;تحدثي إلى طبيبكِ أو الممرضة قبل أن يستخدما هذا الدواء إذا كنتِ مصابة بأي من الحالات التالية أو كنتِ قد أصبتِ بأي منها في السابق حيث قد يرغبان في مراقبة حالتكِ عن كثب بشكل أكبر:</p><ul><li dir="RTL">مرض في القلب، أو الرئة، أو الكلى، أو الكبد</li><li dir="RTL">الزرق (ارتفاع الضغط داخل العين)</li><li dir="RTL">الصرع</li><li dir="RTL">إذا عانيتِ سابقًا من الربو</li><li dir="RTL">ارتفاع ضغط الدم (ضغط الدم المرتفع) في أي وقت، بما في ذلك أثناء هذا الحمل أو أي حمل سابق</li><li dir="RTL">إذا تم إخباركِ بأنكِ أصبتِ بانقباضات قوية بشكل غير طبيعي بالرحم أثناء مخاض سابق</li><li dir="RTL">وجود تندب في رحمكِ من عملية سابقة</li><li dir="RTL">إذا كنتِ بعمر ٣٥ عامًا أو أكبر</li><li dir="RTL">إذا بلغت فترة حملكِ أكثر من ٤٠ أسبوعًا</li><li dir="RTL">إذا كنتِ تعانين من أي مضاعفات مرتبطة بهذا الحمل</li><li dir="RTL">وجود خطر متزايد للإصابة باضطراب نزيف معمم، وهو حالة تعرف باسم التخثر المنتشر بعد الولادة.</li><li dir="RTL">إذا كنت ستلدين أكثر من طفل واحد</li><li dir="RTL">إذا نزل ماء الرحم لديكِ.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">سوف يطرح عليكِ طبيبكِ أو الممرضة أسئلة قبل إعطائكِ محلول التسريب بروستين إي ٢ للتأكد من أنه آمن بالنسبة لكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تفهمي أيًا من الأسئلة، فاطلبي من طبيبكِ أو الممرضة التوضيح.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبري طبيبكِ أو الصيدلي إذا كنتِ تأخذين أو أخذتِ مؤخرًا أو قد تأخذين أي أدوية أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن أن يجعلكِ بروستين إي ٢ أكثر حساسية تجاه دواء آخر، يسمى أوكسيتوسين، يستخدم لتقوية الانقباضات. سوف يحاول الطاقم الطبي في الوضع الطبيعي عدم استخدام هذا الدواء في الوقت نفسه مع بروستين إي ٢. إذا تم استخدامه مع هذا الدواء على التوالي، فسوف يراقب طبيبكِ أو الممرضة انقباضات الرحم بعناية شديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول بروستين إي ٢ مع الطعام والشراب والكحوليات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا ينطبق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>الحمل والرضاعة </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;سوف يتم إعطاء ركازة بروستين إي ٢ لتحضير محلول للتسريب إليكِ فقط في المراحل الأخيرة من الحمل لتحفيز المخاض. يُستخدم محلول بروستين إي ٢ المعقم فقط أثناء الحمل من أجل الإنهاء العلاجي للحمل والإجهاض الفائت والحمل العنقودي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على الرغم من وجود البروستاجلاندينات في حليب الثدي، فلا يُتوقع منك أن تُرضعي رضاعة طبيعية لأن هذا الدواء يستخدم لإنهاء الحمل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات </strong><strong>بروستين إي ٢</strong></p><p dir="RTL"><strong>&nbsp;تحتوي ركازة بروستين إي ٢ لتحضير محلول للتسريب على الكحول (إيثانول)</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي بروستين إي ٢ ٠,٧٥ ملجم على ٦٠٠ ملجم من الكحول (إيثانول) في كل أمبولة ٠,٧٥ مل، أي ما يكافئ ٨٠٠ ملجم/مل (٨٠ ٪ الوزن/الحجم) (انظر القسم ٢). تكافئ الكمية الموجودة في كل أمبولة ٠,٧٥ مل من هذا الدواء أقل من ١٥ مل من البيرة أو ٦ مل من النبيذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي بروستين إي ٢ ٥ ملجم على ٤٠٠ ملجم من الكحول (إيثانول) في كل أمبولة ٠,٥ مل، أي ما يكافئ ٨٠٠ ملجم/مل (٨٠ ٪ الوزن/الحجم) (انظر القسم ٢). تكافئ الكمية الموجودة في كل أمبولة ٠,٥ مل من هذا الدواء أقل من ١٠ مل من البيرة أو ٤ مل من النبيذ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لن يكون للكمية الصغيرة من الكحول الموجودة في هذا الدواء أي آثار ملحوظة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">سيزودكِ هذا المنتج الدوائي بكميات مختلفة من الإيثانول وفقًا للجرعة اليومية المعطاة لكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير بروستين إي ٢ على القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">في ضوء دواعي استعمال بروستين إي ٢، لا ينطبق هذا القسم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاء بروستين إي ٢ لكِ بواسطة أخصائي مدرب في مستشفى أو عيادة حيث تتوفر وسائل لمراقبتكِ أنتِ وطفلكِ. وسيكون طاقم العمل الطبي متاحًا في جميع الأوقات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إرشادات تحضير المحاليل المخففة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">A.&nbsp;&nbsp;&nbsp; من الركازة ١ ملجم/مل لتحضير محلول للتسريب:<br />للاستخدام عن طريق الوريد لتحفيز المخاض (١,٥ ميكروجرام/مل محلول تسريب مخفف).<br />للاستخدام بالتنقيط في الوريد (يجب استخدام جهاز تنقيط لتوصيل ٦٠ نقطة لكل مل) أو مضخة تسريب بمعدل ثابت: اسحب ٠,٧٥ مل من المستحضر ذي التركيز ١ ملجم/مل باستخدام أسلوب معقم، وقم بإضافتها إلى ٥٠٠ مل من محلول ملحي طبيعي معقم أو محلول الدكستروز المائي المعقم بتركيز ٥ ٪.&nbsp; قم برج المحتويات للتأكد من تجانس المحلول.&nbsp; يجب استخدام المحلول المخفف خلال ٢٤ ساعة من التحضير.</p><p dir="RTL">B.&nbsp;&nbsp;&nbsp; من الركازة ١٠ ملجم/مل لتحضير محلول للتسريب:<br />للاستخدام عن طريق الوريد في حالة احتباس الجنين والحمل العنقودي (٥,٠ ميكروجرامات/مل محلول تسريب مخفف).<br />للاستخدام بالتنقيط في الوريد (يجب استخدام جهاز تنقيط لتوصيل ٦٠ نقطة لكل مل) أو مضخة تسريب بمعدل ثابت: اسحب ٠,٥ مل من المستحضر ذي التركيز ١٠ ملجم/مل باستخدام أسلوب معقم، وقم بإضافتها إلى ١٠٠٠ مل من محلول ملحي طبيعي معقم أو محلول الدكستروز المائي المعقم بتركيز ٥ ٪ (أو ٠,٢٥ مل إلى ٥٠٠ مل).&nbsp; قم برج المحتويات للتأكد من تجانس المحلول.&nbsp; يجب استخدام المحلول المخفف خلال ٢٤ ساعة من التحضير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعات</p><p dir="RTL">&nbsp;</p><p dir="RTL">في جميع الحالات، ينبغي ضبط الجرعة وفقًا لحالة المريضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp; لتحفيز المخاض عن طريق الاستخدام في الوريد (١,٥ ميكروجرام/مل محلول مخفف للتسريب):<br />ينبغي أن يكون المعدل المبدئي للتسريب ٠,٢٥ ميكروجرام/دقيقة، وينبغي الاستمرار على هذا المعدل لمدة الـ٣٠ دقيقة الأولى على الأقل.&nbsp; إذا نتجت استجابة انقباضية كافية في الرحم، ينبغي الاستمرار على هذا المعدل.&nbsp; وإذا لم يحدث ذلك، يمكن زيادة المعدل إلى ٠,٥ ميكروجرام/دقيقة.&nbsp; في بعض الحالات، بعد تجربة المعدلات الأخرى بما يكفي (ساعة أو ساعتين)، يمكن زيادة المعدل إلى ١,٠ ميكروجرام/دقيقة أو إلى ٢,٠ ميكروجرام/دقيقة في حالات نادرة لإحداث انقباضات كافية، ولكن ينبغي أن تتم هذه الزيادات مع الانتباه للآثار غير المرغوب فيها ومدى استجابة الرحم.&nbsp; وإذا حدث توتر مفرط في عضلات الرحم أو حدثت ضائقة جنينية، ينبغي وقف التسريب إلى أن تعود حالة المريضة والجنين إلى الوضع الطبيعي.&nbsp; وبعد ذلك قد يوصى بالتسريب بمعدل ٥٠ ٪ من مستوى الجرعة الأخيرة ثم زيادته لاحقًا بحذر.<br />قد تتطلب حالات وفاة الجنين في الرحم جرعات أعلى من تلك المعطاة أعلاه.&nbsp; يمكن استخدام معدل مبدئي قدره ٠,٥ ميكروجرام/دقيقة مع زيادات تدريجية، على فترات لا تقل عن ساعة واحدة كما هو موضح أعلاه.&nbsp; وحسب الآثار غير المرغوب فيها التي تظهر، يمكن زيادة المعدل النهائي للتسريب إلى ٤,٠ ميكروجرامات/دقيقة إذا كانت الاستجابة الانقباضية في الرحم غير كافية بمعدلات الجرعة الأقل. ولا يوصى بالاستخدام المستمر للعقار لأكثر من يومين.</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp; لإدارة حالات احتباس الجنين والحمل العنقودي عن طريق الاستخدام في الوريد (٥,٠ ميكروجرامات/مل محلول مخفف للتسريب):<br />سيكون المعدل المبدئي للتسريب ٢,٥ ميكروجرام/دقيقة، وينبغي الاستمرار على هذا المعدل لمدة الـ٣٠ دقيقة الأولى على الأقل.&nbsp; إذا نتجت استجابة انقباضية كافية في الرحم، ينبغي الاستمرار على هذا المعدل، وإذا لم يحدث ذلك، تنبغي زيادة المعدل إلى ٥ ميكروجرامات/دقيقة.&nbsp; إذا لم ينتج نشاط كاف للرحم بعد ٤ ساعات على الأقل بمعدل التسريب هذا، يمكن زيادة المعدل لما يصل إلى ١٠ ميكروجرامات/دقيقة، حسب الآثار غير المرغوب فيها التي تظهر، والاستمرار عليه لحين حدوث تفريغ محتوى الرحم وإلا سيعتبر العلاج فاشلًا. &nbsp;وإذا حدثت آثار غير مرغوب فيها ملحوظة، ينبغي خفض معدل التسريب بنسبة ٥٠ ٪ أو إيقافه.<br />وفقًا لنوع مضخة التسريب، قد يتطلب الأمر تركيزًا مختلفًا للمحلول (على سبيل المثال ١٥ ميكروجرام/مل)، ولكن يجب أن يبقى معدل الجرعة المسربة (ميكروجرام/دقيقة) كما هو موضح أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يراقب الطبيب أو الممرضة حالتكِ عن كثب أثناء علاجكِ للتأكد من أن الانقباضات لم تصبح أقوى من اللازم، حيث قد يسبب ذلك تمزق الرحم. ويُفترض أن يكونا قادرين على التصرف بشكل سريع إذا أصبتِ بآثار جانبية أو تفاعل رحمكِ بصورة أقوى من اللازم تجاه الجرعة المعطاة لكِ. قد تحتاجين فقط إلى جرعة أقل أو قد تحتاجين إلى الخضوع إلى شكل آخر من أشكال إجراءات الولادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>فئة المرضى من</em><em> الأطفال</em></p><p dir="RTL">لم تثبُت سلامة وفعالية بروستين إي ٢ لدى المرضى من الأطفال. لا يوجد استخدام مناسب لبروستين إي ٢ مع المرضى من الأطفال بخلاف ذلك الخاص بالمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الزائدة من بروستين إي ٢</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أخبري طبيبكِ أو الممرضة إذا كنتِ تعتقدين أنه تم إعطاؤك جرعة أكبر مما ينبغي من بروستين إي ٢. ستكون أعراض ذلك الانقباضات المفرطة في الرحم (انقباضات قوية ومتكررة ومؤلمة جدًا) أو الآثار الجانبية الشديدة مثل الشعور بالرغبة في التقيؤ والقيء. إذا كنتِ تعانين من مثل هذه الأعراض، ينبغي تقليل معدل إعطاء بروستين إي ٢ أو ينبغي وقف العلاج. إذا أخذتِ جرعة مفرطة ضخمة بحيث أصبحت عضلات رحمكِ مشدودة للغاية ومفرطة النشاط أو تمزقت، فقد تحتاجين إلى الخضوع لإجراء آخر للولادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يجري طبيبكِ أو الممرضة فحوصات داخلية للتأكد من أن عنق الرحم لديكِ يتوسع بما يكفي. وسيقومان أيضًا بفحص انقباضاتكِ للتأكد من أنها ليست أقوى من اللازم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ مصابة بالربو، فقد يتسبب بروستين إي ٢ في إصابتكِ بنوبة ربو عن طريق التسبب في تضييق المسالك الهوائية لديكِ (التشنج القصبي). <strong>يجب عليكِ إخبار طبيبكِ أو الممرضة إذا كنتِ تعانين من الربو أو إذا بدأتِ تعانين من صعوبة في التنفس.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تتضمن الأعراض الجانبية الأخرى المُبلّغ عنها:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;آثار جانبية شائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستفراغ (القيء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (الشعور بالرغبة في التقيؤ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقباضات قوية أو متكررة أو طويلة بشكل غير طبيعي بالرحم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بانزعاج أو احمرار في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض درجة اختبار أبغار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدل غير طبيعي لنبضات قلب الجنين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; أعراض وعائية مبهمية (الاحمرار، الارتعاش، الصداع، الدوار)</p><p dir="RTL">&middot;&nbsp;&nbsp; ارتفاع ضغط دم الأم</p><p dir="RTL">&middot;&nbsp;&nbsp; الضائقة الجنينية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>غير شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp; النوبات</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp; التشنج القصبي</p><p dir="RTL">&middot;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp; انفصال المشيمة</p><p dir="RTL">&middot;&nbsp;&nbsp; الإصابة بارتفاع في درجة الحرارة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>نادرة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص)</u></strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp; النزيف</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ذات معدل تكرار غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتاحة</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp; انسداد مفاجئ في أحد الأوعية الدموية الخاصة بالسائل السلوي (السائل المحيط بالجنين) أو بسبب جلطة دموية في الرئتين. يمكن أن يسبب ذلك ألم الصدر وضيق التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp; اتساع عنق الرحم بسرعة كبيرة</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp; موت الجنين، وولادة جنين ميت، وموت الطفل المولود (وفاة حديثي الولادة)؛ خاصة بعد الأحداث الخطيرة مثل تمزق الرحم</p><p dir="RTL">&middot;&nbsp;&nbsp; تمزق أو انفجار جدار الرحم (التمزق الرحمي)</p><p dir="RTL">&middot;&nbsp;&nbsp; النوبة القلبية</p><ul><li dir="RTL">تفاعلات حساسية/تأقية، بما في ذلك الصدمة التأقية (تفاعلات حساسية خطيرة يمكن أن تتضمن الطفح الجلدي، والحكة، والأزيز، وضيق التنفس، وتورم الوجه والشفتين واليدين والأصابع والرقبة والحلق، والانخفاض المفاجئ في ضغط الدم، وألم البطن، والهبوط).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أصبتِ بأي من هذه الأعراض، يُرجى إخبار طبيبكِ أو الممرضة على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدثي إلى طبيبكِ أو الممرضة بشأن هذا الأمر إذا كنتِ ترغبين في معرفة المزيد، حيث سيكونان قادرين على إعطائكِ المعلومات التي تحتاجين إليها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لدى بعض السيدات، يرتفع عدد خلايا الدم البيضاء أثناء العلاج. لن يسبب لكِ ذلك أي أعراض ولكن قد يذكر طبيبكِ أو الممرضة ذلك إذا خضعتِ لسحب عينة دم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تعانين من احمرار وتهيج في المنطقة المحيطة بموضع الحقن لمدة ساعتين إلى خمس ساعات بعد إزالة الإبرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد وصف وجود خطر أكبر للإصابة باضطراب نزيف معمم بعد الولادة (التخثر المنتشر داخل الأوعية الدموية (DIC) بعد الولادة) في السيدات اللاتي:</p><ul><li dir="RTL">&nbsp;يبلغن من العمر ٣٥ عامًا فأكثر.</li><li dir="RTL">تخطت فترة حملهن ٤٠ أسبوعًا.</li><li dir="RTL">يعانين من مضاعفات مرتبطة بالحمل.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الإبلاغ عن الأعراض الجانبية:<br />إذا أُصبتِ بأي أعراض جانبية، فتحدثي إلى طبيبك أو الصيدلي. يتضمن ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنكِ المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;المركز الوطني للتيقظ الدوائي (NPC):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد : ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong>دول الخليج الأخرى:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:575px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُخزن في الثلاجة (٢‑٨ درجات مئوية).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ بروستين إي ٢ بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;لا يُستخدم بروستين إي ٢ بعد تاريخ انتهاء الصلاحية المُبين على الملصق الموجود على العبوة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلصي من أي أدوية عبر مياه الصرف. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعودي تستخدمينها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي ركازة بروستين إي ٢ ٠,٧٥ ملجم المُستخدمة لتحضير محلول للتسريب على ١ ملجم من دينوبروستون في ١ مل من المحلول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي ركازة بروستين إي ٢ ٥ ملجم المُستخدمة لتحضير محلول للتسريب على ١٠ ملجم من دينوبروستون في ١ مل من المحلول.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى:</p><p dir="RTL">&nbsp;</p><p dir="RTL">- بروستين إي ٢ ركازة ٠,٧٥ ملجم لتحضير محلول للتسريب: إيثانول لا مائي.</p><p dir="RTL">- بروستين إي ٢ ركازة ٥ ملجم لتحضير محلول للتسريب: إيثانول لا مائي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروستين إي ٢&nbsp; ركازة ٠,٧٥ ملجم لتحضير محلول للتسريب: أمبولة واحدة تحتوي على ٠,٧٥ مل من المحلول بتركيز ١ ملجم/مل.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروستين إي ٢&nbsp; ركازة ٥ ملجم لتحضير محلول للتسريب: أمبولة واحدة تحتوي على ٠,٥ مل من المحلول بتركيز ١٠ ملجم/مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم طرح جميع أشكال العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك تصريح التسويق </strong></p><p>Pfizer S.A., 17 Boulevard de la Plaine, 1050 Brussels, Belgium، بلجيكا.</p><p>&nbsp;</p><p><strong>الجهة المصنعة</strong><strong>، المعبئة والموزعة</strong><strong>:</strong></p><p>&nbsp;&nbsp;&nbsp; Pfizer Manufacturing Belgium N.V, Rijsweg 12, Puurs, Belgium</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس/آب ٢٠٢١
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PROSTIN E2   0.75 mg concentrate for solution for infusion
PROSTIN E2   5 mg concentrate for solution for infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PROSTIN E2 0.75 mg concentrate for solution for infusion contains 1 mg dinoprostone in 1 ml solution.
PROSTIN E2 5 mg concentrate for solution for infusion contains 10 mg dinoprostone in 1 ml solution.

Excipient with known effect: anhydrous ethanol
PROSTIN E2 0.75 mg contains 600 mg of alcohol (ethanol) in each 0.75 ml ampoule which is equivalent to 800 mg/ml (80% w/v).
PROSTIN E2 5 mg contains 400 mg of alcohol (ethanol) in each 0.5 ml ampoule which is equivalent to 800 mg/ml (80% w/v). 
  
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PROSTIN E2 is indicated for the following indications:</p><p>A.&nbsp; Artificial induction of labor.<br />PROSTIN E2&nbsp;&nbsp; 0.75 mg&nbsp; concentrate for solution for infusion &agrave; 1 mg/ml:</p><p>1.&nbsp;&nbsp; Therapeutic induction of labor when there are no foetal or maternal contraindications.</p><p>2.&nbsp;&nbsp; Induction of labor in cases of fetal death in utero.</p><p>&nbsp;</p><p>B.&nbsp;&nbsp; Management of fetus retention and hydatidiform mole.</p><p>PROSTIN E2 5 mg concentrate for solution for infusion &agrave; 10 mg/ml:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROSTIN E2 can be used for evacuation of the uterine content in cases of fetus retention (spontaneous abortion).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROSTIN E2 is useful as non‑surgical treatment for the evacuation of hydatidiform mole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Usage is restricted to qualified health care professionals and to hospitals and clinics with specialised obstetric units with facilities for continuous monitoring.</p><p>&nbsp;</p><p>The recommended dose should not be exceeded, and the dosing interval should not be shortened as this increases the risk of uterine hyperstimulation, uterine rupture, uterine haemorrhage, foetal and neonatal death.</p><p>&nbsp;</p><p>DIRECTIONS FOR THE PREPARATION OF DILUTED SOLUTIONS</p><p>A.&nbsp;&nbsp;&nbsp; From the 1 mg/ml concentrate for solution for infusion:<br />For intravenous use for the induction of labor (1.5&nbsp;micrograms/ml dilute infusion).<br />For use by IV drip (a drip set delivering 60 drops per ml must be used) or constant rate infusion pump: withdraw 0.75 ml of the 1&nbsp;mg/ml preparation using an aseptic technique, and add to 500&nbsp;ml sterile normal saline or 5% sterile aqueous dextrose solution.&nbsp; Shake to ensure uniformity.&nbsp; Diluted solution must be used within 24 hours of preparation.</p><p>B.&nbsp;&nbsp;&nbsp;&nbsp; From the 10 mg/ml concentrate for solution for infusion:<br />For intravenous use for fetus retention and hydatidiform mole (5.0&nbsp;micrograms/ml dilute infusion).<br />For use by IV drip (a drip set delivering 60 drops per ml must be used) or a constant rate infusion pump: withdraw 0.5&nbsp;ml of the 10&nbsp;mg/ml preparation using an aseptic technique, and add to 1000&nbsp;ml sterile normal saline or 5% sterile aqueous dextrose solution (or 0.25 ml to 500 ml).&nbsp; Shake to ensure uniformity.&nbsp; Diluted solution must be used within 24 hours of preparation.</p><p>&nbsp;</p><p>POSOLOGY</p><p>In all cases the dose should be adapted to the patient.</p><p>1.&nbsp;&nbsp;&nbsp; For induction of labor by the intravenous route (1.5 micrograms/ml diluted solution for infusion):<br />The initial rate of infusion should be 0.25 micrograms/min, which should be maintained for at least the first 30 minutes.&nbsp; If a satisfactory uterine contractility response is produced, this rate should be maintained.&nbsp; If not, the rate may be increased to 0.5&nbsp;micrograms/min.&nbsp; In some circumstances, after a fair trial (one or two hours), the rate may be increased to 1.0 micrograms/min or, rarely, 2.0 micrograms/min to produce a satisfactory contractility, but increases should be made in the light of undesirable effects and uterine response.&nbsp; If uterine hypertonus or fetal distress occurs, the infusion should be stopped until the condition of the patient and the fetus returns to normal.&nbsp; The infusion may then be recommended at 50% of the last dose level and subsequently increased with caution.<br />Cases of foetal death in utero may require higher doses than those given above.&nbsp; An initial rate of 0.5 micrograms/min may be used with gradual increases at intervals of not less than one hour as described above.&nbsp; Undesirable effects permitting, the final rate of infusion may be increased to 4.0&nbsp;micrograms/min if uterine contractility response is inadequate at the lower dosage rates. Continuous administration of the drug for more than two days is not recommended.</p><p>2.&nbsp;&nbsp;&nbsp; For the management of fetus retention and hydatidiform mole by the intravenous route (5.0 mcg/ml diluted solution for infusion):<br />The initial rate of infusion will be 2.5 micrograms/min, and this rate should be maintained for at least the first 30 minutes.&nbsp; If satisfactory uterine contractility response is produced, this rate should be maintained; if not, the rate should be increased to 5 micrograms/min.&nbsp; If satisfactory uterine activity is not produced after at least 4 hours at this rate of infusion, the rate may be increased up to 10 micrograms/min, undesirable effects permitting, and maintained until evacuation of the uterine content occurs or the treatment is considered a failure.&nbsp; If significant undesirable effects occur, the rate of infusion should be decreased by 50% or discontinued.<br />Dependent on the type of infusion pump, a different concentration of solution (e.g. 15 micrograms/ml) may be required, but the infused dose rate (mcg/min) should remain as above.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Prostin E2 in paediatric patients has not been established.&nbsp; There is no relevant use of Prostin E2 in paediatric patients other than adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Administration of PROSTIN E2 is contraindicated:
1.	In patients with hypersensitivity to dinoprostone or to any of the excipients listed in section 6.1.
2.	In patients in whom oxytocic drugs are generally contraindicated, in case of :
	multiparity (six or more previous term pregnancies);
	engagement of the head has not taken place;
	previous uterine surgery (after cesarean section, hysterectomy, etc.);
	cephalopelvic disproportion;
	fetal heart rate pattern suggests incipient fetal compromise;
	obstetric conditions where either maternal or fetal benefit/risk ratio favors surgical intervention;
	unexplained vaginal discharge and/or abnormal uterine bleeding during current pregnancy; 
	non-vertex presentation 
	vascular pathology (in particular coronary disease); 
	heart-decompensation, severe continuous arterial hypertension;
	history of difficult and/or traumatic delivery.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This product is for use in hospitals only and administered under medical surveillance.</p><p>&nbsp;</p><p>Patients with known pelvic infections should first of all receive adequate treatment.</p><p>&nbsp;</p><p>As with any oxytocic agent, the risk of uterine rupture should be considered. Concomitant medication, maternal and foetal status should be taken into consideration in order to minimise the risk of uterine hyperstimulation, uterine rupture, uterine haemorrhage, foetal and neonatal death. Continuous electronic monitoring of uterine activity and foetal heart rate should be conducted during use of dinoprostone. Patients who develop uterine hypertonus or hypercontractility, or in whom unusual foetal heart rate patterns develop, should be managed in a manner that addresses the welfare of the foetus and mother.</p><p>&nbsp;</p><p>Dinoprostone should be used with caution in patients with impaired cardiovascular, hepatic or renal function, asthma, glaucoma or raised intraocular pressure, or ruptured chorioamniotic membranes. Dinoprostone should be used with caution in patients with multiple pregnancy.</p><p>&nbsp;</p><p>Severe cardiovascular accidents, potentially fatal (myocardial infarction and/or ventricular fibrillation) have been reported with prostaglandins and prostaglandin analogues for injection. The risk of such accidents increases with age, chronic smoking and recent smoking.&nbsp; As a precautionary measure, female patients should be asked not to smoke during the days prior to dinoprostone administration.</p><p>Consequently it is necessary:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To take into account these risks in female patients over 35 years old and in women who smoke;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To take into account other cardiovascular risk factors (hyperlipidemia, diabetes, family history);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of suspected coronary spasm (thoracic pain, rhythm disorders, significant arterial hypotension, cardiovascular collapse, fainting) an ECG must be performed immediately;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the ECG confirms diagnosis of coronary spasm, it is necessary to use injectable nitrate derivatives or injectable calcium antagonists as rapidly as possible since antithrombotic treatment is not appropriate for this kind of disorder.</p><p>&nbsp;</p><p>Women aged 35 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks have been shown to have an increased risk of post-partum disseminated intravascular coagulation. In addition, these factors may further increase the risk associated with labour induction (see section 4.8). Therefore, in these women, use of dinoprostone should be undertaken with caution. Measures should be applied to detect as soon as possible an evolving fibrinolysis in the immediate post-partum phase.</p><p>&nbsp;</p><p>In labor induction, cephalopelvic compatibility must be carefully evaluated before use of PROSTIN E2. Labor progression (dilatation, engagement) must be closely monitored during, and certainly also after the induction.</p><p>&nbsp;</p><p>The use of PROSTIN E2 concentrate for solution for infusion is restricted to large, well equipped obstetric clinics with competent and permanently available medical and paramedical staffs.</p><p>&nbsp;</p><p>The induction of labour in general is associated with the risk of amniotic fluid embolism (AFE) (also called Anaphylactoid syndrome of pregnancy). Cases of AFE have been reported after the use of different formulations of dinoprostone for cervical maturation (see section 4.8). The onset is often abrupt during labour and delivery/caesarean section or up till 48 hours post-partum.</p><p>&nbsp;</p><p><u>Excipient information</u></p><p>PROSTIN E2 0.75 mg contains 600 mg of alcohol (ethanol) in each 0.75 ml ampoule which is equivalent to 800 mg/ml (80% w/v) (see section 2). The amount in each 0.75 ml ampoule of this medicine is equivalent to less than 15 ml beer or 6 ml wine.</p><p>PROSTIN E2 5 mg contains 400 mg of alcohol (ethanol) in each 0.5 ml ampoule which is equivalent to 800 mg/ml (80% w/v) (see section 2). The amount in each 0.5 ml ampoule of this medicine is equivalent to less than 10 ml beer or 4 ml wine.</p><p>&nbsp;</p><p>The small amount of alcohol in this medicine will not have any noticeable effects, certainly not after dilution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The response to oxytocin may be accentuated in the presence of exogenous prostaglandin therapy. Concurrent use with other oxytocic agents is not recommended. A dosing interval of at least 6 hours is recommended in case of oxytocin use is considered necessary following dinoprostone administration.</p><p>&nbsp;</p><p>Therefore, it is recommended to carefully monitor the patient if these drugs are used in sequence.&nbsp; Because prostaglandins have multiple pharmacological effects, simultaneous administration of NSAIDs or other substances altercating on prostaglandins metabolism requires special caution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>There are no clinical data available on the effects of dinoprostone on fertility.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>PROSTIN E2 is indicated for treatment of pregnant women for use before term or during delivery.</p><p>Any dose that produces sustained increased uterine tone could put the embryo or foetus at risk (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p>Animal studies have confirmed reproductive toxicity (see section 5.3)&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Lactation </strong></p><p>Prostaglandins are excreted in breast milk at very low concentrations.&nbsp; No measurable differences were observed in the milk of mothers delivering prematurely and at term.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Safety profile</u></p><p>&nbsp;</p><p>The most commonly reported adverse drug reactions in clinical trials for intravenous formulation of dinoprostone (occurring in &gt;10% of patients) are diarrhoea, nausea, vomiting in the mother, abnormal uterine contractions, injection site erythema, injection site irritation, low APGAR score and abnormal foetal heart rate in the infant.&nbsp;</p><p>Other adverse events reported in up to 10% of patients are vasovagal symptom (flushing, shivering, headache, dizziness), hypertension and foetal distress syndrome.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The table below lists the adverse effects by System Organ Class (SOC) and frequency. Within each frequency grouping, adverse events are presented in order of decreasing seriousness. Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), or not known (cannot be estimated from the available data).&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:690px"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Disseminated intravascular coagulation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic shock, Anaphylactic reaction, Anaphylactoid reaction (including anaphylactoid syndrome of pregnancy), Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasovagal symptom (flushing, shivering, headache, dizziness)</p></td><td style="vertical-align:top"><p>Convulsion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac arrest</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthma, Pulmonary oedema, Dyspnoea, Apnoea</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea, Nausea, Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Pregnancy, puerperium and perinatal conditions</p></td><td style="vertical-align:top"><p>Uterine contractions abnormal</p></td><td style="vertical-align:top"><p>Foetal distress syndrome</p></td><td style="vertical-align:top"><p>Abruptio placentae</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amniotic fluid&nbsp; embolism, Uterine rupture, Rapid cervical dilatation, Foetal death<sup>&sect;</sup>, Stillbirth<sup>&sect;</sup>, Neonatal death<sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site erythema, Injection site irritation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>APGAR score low, Foetal heart rate abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>White blood cell count increased</p></td></tr></tbody></table><p><sup>&sect; </sup>Foetal death, stillbirth, and neonatal death have been reported after application of dinoprostone, especially following the occurrence of serious events such as uterine rupture (see sections 4.2, 4.3 and 4.4).</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Management of fetal retention, and hydatidiform mole (10&nbsp;mg/ml).</strong><br />Clinical studies have shown that recommended dosages did not induce life threatening undesirable effects.&nbsp; When seen, undesirable effects have generally been dose‑dependent, transient, and reversible on discontinuation of therapy.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>In isolated cases:</strong> in predisposed patients bronchoconstriction can occur.</p><p><u>&nbsp;</u></p><p><strong>Post-marketing surveillance</strong></p><p><em>Blood and lymphatic system disorders<strong>:&nbsp; </strong></em>An increased risk of post-partum disseminated intravascular coagulation has been described in patients whose labor was induced by pharmacological means, either with dinoprostone or oxytocin (see section 4.4).&nbsp; The frequency of this adverse event, however, appears to be rare (&lt;1 per 1,000 labors).</p><p><em>Pregnancy, puerperium and perinatal conditions: </em>Labour induction has been associated with the risk of anaphylactoid syndrome of pregnancy (amniotic fluid embolism (AFE)) (see section 4.4).&nbsp;&nbsp; The precise physiopathology of AFE remains unexplained but the crossing of amniotic liquid components into the maternal circulation has been incriminated in the occurrence of an anaphylactoid reaction and mechanical obstruction of the pulmonary capillaries leading to major hemodynamic, haemorrhagic and neurological problems.&nbsp; The most frequently reported clinical signs are acute hypotension, cardiac arrest, cardiac arrhythmias, agitation-type prodromes and sensation of malaise, convulsions, cyanosis, dyspnoea or acute respiratory distress, foetal distress, maternal haemorrhage associated in the majority of the cases to a disseminated intravascular coagulation. These clinical signs can appear separately or in combination.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance&nbsp; Centre ( NPC )</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdosage may be uterine hypercontractility or uterine hypertonus.</p><p>Because of the transient nature of PGE2-induced myometrial hyperstimulation, nonspecific, conservative management was found to be effective in the vast majority of the cases; i.e., maternal position change and administration of oxygen to the mother.</p><p>If uterine overstimulation (and/or foetal distress) is not resolved by discontinuation of the treatment, intravenous administration of a beta-2-mimetic can be useful. If tocolytic treatment is also unsuccessful,&nbsp; immediate delivery is indicated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: oxytocics</p><p>ATC code: G02AD02</p><p>&nbsp;</p><p>Dinoprostone or prostaglandin E2 belongs to a family of naturally occurring unsaturated fatty acids.</p><p>Prostaglandins possess a wide range of pharmacological activities, including the ability to stimulate smooth muscle containing organs and to modulate organ responses to other hormonal stimuli.</p><p>Dinoprostone induces rhythmical uterine contractions which, if continued for a sufficient time, are capable of expelling the uterine content.</p><p>In contrast with oxytocin, dinoprostone is influencing the uterine activity on every given time during pregnancy and has no antidiuretic effect.</p><p>Sensitivity of the pregnant woman to dinoprostone is lower during first and second trimester of the pregnancy than during last trimester.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Natural prostaglandins are produced very quickly from corresponding free polyunsaturated fatty acids.&nbsp; Even in minimal amounts, these substances induce significant modifications, after which they are rapidly converted into non-active metabolites.&nbsp; After intravenous injection, the half‑life of dinoprostone is less than one minute, whereas the half‑life of all its primary metabolites is about eight minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data resulting from conventional safety pharmacology, repeated administration toxicology and genotoxicity studies did not show any particular risk to humans.</p><p>&nbsp;</p><p>In rats, when the mother received subcutaneous daily doses of 3.3 mg/kg/day, some slight teratogenic effects, causing skeletal abnormalities, were observed. Also, evidence of embryotoxicity has also been observed, probably resulting from the increased uterine tone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anhydrous ethanol (see section 4.4 &ndash; Excipient information).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use PROSTIN E2   after the expiry date which is stated on the Ampoule label after EXP:. The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;‑8&deg;C).</p><p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PROSTIN E2&nbsp;&nbsp; 0.75 mg concentrate for solution for infusion: 1 ampoule with 0.75 ml solution 1 mg/ml.</p><p>PROSTIN E2&nbsp;&nbsp; 5 mg concentrate for solution for infusion: 1 ampoule with 0.5 ml solution 10 mg/ml.</p><p>&nbsp;</p><p>Not all presentations may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with current requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer S.A., 17 Boulevard de la Plaine, 1050 Brussels, Belgium. 

MANUFACUTRED, PACKED & RELEASED BY

Pfizer Manufacturing Belgium N.V, Rijsweg 12, Puurs, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>